Bedinvetmab (Librela<sup>®</sup>), a fully canine anti-nerve growth factor monoclonal antibody, was compared to the non-steroidal anti-inflammatory drug (NSAID) meloxicam in dogs for the management of osteoarthritis-related pain in a randomised, open-label, multicentre, parallel-group study. This evidence concerns the gene NGF and osteoarthritis.